



The Roles of Genomics and Proteomics in Human Parasitology: Closing the Knowledge Gap

ARTICLE INFO

Article Type Review Article

Authors

Akinseye Janet Funmilayo, PhD¹
Oluwaseun Agboola, MSc²
Samuel Agboola, PhD³
Bernard Oluboyo, PhD⁴
Adebimpe Egbebi, PhD⁵
Abayomi Sijuade, PhD⁶
Zainab Ayinla, PhD⁷
Adekunle Adegbuyi, PhD⁸
Chidera Agu, PhD⁹
Victoria Aikhomu, PhD¹⁰
Ogunbala Ogunfolakan, PhD¹¹
Juliet Onyejiaka, PhD¹²
Tunrayo Oludare, PhD¹³
Adeorite Agboola, PhD¹⁴

¹ Medical Laboratory Science Department, College of Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, Nigeria

² Institute for Drug Research and Development, Bogoro Research Centre, Afe Babalola University, Ado-Ekiti, Nigeria

³ Department of Pharmacology and Toxicology, College of Pharmacy, Afe Babalola University, Ado-Ekiti, Nigeria

⁴ Medical Laboratory Science Department, College of Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, Nigeria

⁵ Medical Laboratory Science Department, College of Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, Nigeria

⁶ Department of Pharmacology and Therapeutic, College of Medicine, Ekiti State University, Ekiti State, Nigeria

⁷ Department of Biochemistry and Molecular Biology, Obafemi Awolowo University, Ile-Ife, Nigeria

⁸ Department of Pharmacology and Toxicology, Faculty of Pharmacy, Federal University Oye-Ekiti, Nigeria

⁹ Department of Community Medicine, College of Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti

¹⁰ Integrated Medical Sciences Department, College of Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, Nigeria

* Correspondence

Medical Laboratory Science Department, College of Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, Nigeria.

E-mail: akinseyejf@abuad.edu.ng

How to cite this article

Funmilayo A.J., Agboola O., Agboola S., Oluboyo B., Egbebi A., Sijuade A., Ayinla Z., Adegbuyi A., Agu Ch., Aikhomu V., Ogunfolakan O., Onyejiaka J., Oludare T., Agboola A. The Roles of Genomics and Proteomics in Human Parasitology: Closing the Knowledge Gap. *Infection Epidemiology and Microbiology*. 2024;10(2): 157-174

Article History

Received: August 17, 2023

Accepted: April 05, 2024

Published: June 21, 2024

ABSTRACT

Background: The complicated host-parasite relationships have hindered the effective diagnosis, treatment, and control of human parasitic diseases. This review examines how genomics and proteomics are unraveling these complex interactions and transforming human parasitology.

Materials & Methods: Related studies were chosen according to the PRISMA flow diagram. An extensive literature search between January 1, 2022 and March 31, 2023 was conducted in PubMed, Scopus, and Web of Science databases, and a systematic screening process was undertaken, resulting in the identification and inclusion of 72 studies in this narrative review on the applications of genomics and proteomics in human parasitology research. Articles that were duplicates, irrelevant based on title/abstract screening, unavailable, or irrelevant based on full text review were excluded from the study.

Findings: A total of 453 records were retrieved, of which 72 articles remained after title, abstract, and full text screening. Genomics and proteomics have elucidated parasite biology, enabled precision diagnostics, and guided drug development by providing molecular insights into host-parasite interactions. However, challenges remain, including computational complexity and translation of findings to human infections.

Conclusion: The integration of genomics and proteomics has allowed an unprecedented understanding of human parasites and holds great promise for improving diagnosis, treatment, and control.

Keywords: Parasitology, Genomics, Proteomics, Biomarkers, Drug discovery

CITATION LINKS

[1] Runghen R, et al. Network analysis... [2] Bock C, et al. High... [3] Nisar N, Proteomics... [4] Elmore LW, Blueprint ... [5] Dubey AK, Exploring... [6] Amselem J. Genomic ... [7] Campaner R. Explaining... [8] Zhang YD. Genome... [9] Emerson D. Identifying... [10] Sundar S. Understanding... [11] Volkman SK. Harnessing... [12] Lindner SE. Transcriptomics... [13] Reece SE. The life... [14] Alfiky A. Deciphering... [15] Rimbaud L. Durable ... [16] Schröttner P. Characterization... [17] Nesse RM. Evolutionary... [18] Amandine C. Unraveling ... [19] Zerr I. Prion... [20] Arya PK. Databases ... [21] Montarry J. Recent... [22] Waiho K. Protein... [23] Osborne A. Characterizing... [24] Njoku K. Proteomic... [25] Rodrigues-Luiz GF. TipMT... [26] Ding Z. Proteomics... [27] Meissner F. The emerging ... [28] Ofit K. Personalized... [29] Velez G. Personalized... [30] Mannino DM. COPD... [31] Lee M. Deep... [32] Davy SK. Cell biology... [33] Sapountzis P. Microbial... [34] Edwards D. The early... [35] Kaur R. Living... [36] Van den Broeck WM. Drug... [37] Santos BF. Many... [38] Marwaha S. A guide... [39] Razin S. Molecular... [40] Chen L. Deep... [41] Ezkurdia I. Multiple... [42] Kwok AJ. Host... [43] Trapp J. Genomics... [44] Blay V. High... [45] John A. Patient... [46] Trujillo AE. Comparative... [47] Powell R. The... [48] Easton A. Molecular... [49] Rabaan AA. Omics... [50] Barylyuk K. A comprehensive... [51] Serajian S. CRISPR... [52] Hastings JF. Applications... [53] Sotillo J. Trematode... [54] Ittiprasert W. Advances... [55] Muñoz JF. Genomic... [56] Prokop JW. Computational... [57] Aggarwal S. Post... [58] Wang L. Multiomics... [59] Hauser AS. Trends... [60] Loiseau C. Deciphering... [61] Liu D. Bridging... [62] Alaridah N. Transmission... [63] Proietti C. Immune... [64] Naung MT. Global... [65] Varela ML. Practical... [66] Ruybal-Pesántez S. Molecular... [67] Costain AH. Dynamics... [68] Kent RS. Paving... [69] Wörheide MA. Multi... [70] Misra BB. Integrated... [71] Karczewski KJ. Integrative... [72] Antonelli L. Integrating... [73] Nisa RU. Shift... [74] Gabaldón T. Recent... [75] Thaenkham U. Challenges... [76] Jiang L. Infection... [77] Alexandratos A. The... [78] Coutinho JV. The... [79] Tonkin-Hill GQ. The... [80] Rashidi S. Mining...

Introduction

The complex interactions between parasites and their human hosts have historically imposed barriers to identifying disease-causing mechanisms and developing effective treatments in the field of human parasitology ^[1]. This comprehensive review illuminates the potential of genomics and proteomics to revolutionize diagnostics and therapeutics by providing unprecedented insights into these complicated host-parasite relationships ^[2]. With a focus on “The Roles of Genomics and Proteomics in Human Parasitology: Closing the Knowledge Gap”, this review explores how cutting-edge omics technologies have revealed new knowledge about parasite genetics, protein expression, and molecular interactions, transforming our understanding and enabling novel applications ^[3].

The symbiotic relationship between parasites and humans has made it difficult to uncover the intricacies of how parasites establish infections and evade host immunity ^[4]. However, genomics and proteomics are providing unparalleled perspectives to elucidate these complexities among diverse human parasitic species ^[5]. Advances in high-throughput sequencing and proteomic profiling have uncovered the genetic blueprints and protein expression patterns of major parasites.

These molecular perspectives provide a comprehensive understanding of the sophisticated techniques parasites use to exploit hosts and evade immune clearance. Excitingly, genomics and proteomics have moved beyond just advancing basic knowledge to discoveries are empowering new precision medicine approaches that take advantage of molecular vulnerabilities unique to each parasite. A revolution is also underway in drug development, where omics data guide the design of improved antiparasitic medications and the analysis

of drug effects. Additionally, genomics and proteomics have revolutionized diagnostics by facilitating species identification and early detection and providing tailored diagnostic platforms.

Objectives: In essence, this extensive research shows how the synergy between genomics and proteomics has revealed the way forward in human parasitology. These disciplines are ushering us into a new era of diagnostic and therapeutic development by deciphering the complicated host-parasite interactions at the molecular level. The following sections dive deeper into the revolutionary potential of genomics and proteomics in human parasitology, emphasizing their far-reaching implications for improved diagnosis and treatment.

Materials and Methods

An initial search between January 1, 2022 and March 31, 2023 of academic databases including PubMed, Scopus, and Web of Science yielded 453 articles. Related studies were chosen according to the PRISMA flow diagram. After removing duplicates, 342 records remained. These articles were screened by title and abstract review based on the inclusion criteria, including original studies focused on human parasitology utilizing genomics and/or proteomics approaches. This process resulted in the exclusion of 250 articles. The remaining 92 full-text articles were assessed for eligibility, and 72 studies met the criteria to be included in this narrative review. The reasons for excluding some articles were non-English text language, lack of access to the full text or relevance based on the focus of this review. The search was conducted using combinations of keywords including “parasitology”, “genomics”, “proteomics”, “biomarkers”, “drug discovery”, and related terms. Boolean operators (AND, OR) were used to refine the search strategy.

Findings/Discussion

A total of 453 records were retrieved through searching the academic databases including PubMed, Scopus, and Web of Science; potentially related articles were identified after removing 111 duplicate articles. In the following step, 250 articles were excluded after screening their titles and abstracts for inclusion and exclusion criteria. The remaining 92 full-text articles were finally assessed for eligibility, and 72 studies met the criteria to be included in this narrative review (Figure 1).

Human parasitology transformation: Human parasitology is undergoing tremendous changes, propelled by the combination of genomics and proteomics, as these changes deal with the major changes that these technologies have brought about in the area of human parasitology [6]. Historically, research on parasitic diseases has frequently been in unexplored territory, hampered by the complexities of host-parasite interactions and the lack of appropriate instruments for deciphering molecular nuances [7]. The advent of genomics and proteomics has shone a bright light on this complex environ-

ment, revealing mysteries hidden inside genetic coding and protein networks [6, 7].

Genomics provides an aerial perspective of parasitic organisms' genetic blueprints, revealing their survival strategies and virulence mechanisms [7-9].

Researchers are uncovering genetic modifications that allow parasites to infiltrate host defenses, escape immune responses, and establish footholds inside the host environment by decoding the

genomes of diverse parasites [8, 9]. These genetic discoveries lay the groundwork for comprehending the complex molecular characteristics of host-parasite relationships [6]. Proteomics, on the other hand, provides a dynamic narrative of the protein dialogues that orchestrate parasitic infections [6, 7]. Proteomic investigations capture the detailed discussions that occur between parasites and hosts, offering light on the molecular maneuvers that influence the course of infection [7, 8]. These findings shed light on parasites' techniques used to hijack host machinery and manipulate immune responses, as well as countermeasures host cells adopt to protect against invaders [6-8]. This accura-




Figure 1) PRISMA 2009 flow diagram of the studies included in the current narrative review

cy enables healthcare providers to make educated decisions and personalize therapies to particular patient profiles [8, 9]. Furthermore, as genomics and proteomics reveal novel pharmacological targets and lead to the creation of tailored therapeutic treatments, drug development is also set for a revolution [7, 8]. This transition extends to vaccine development, where the discovery of genetic and protein markers specific to diverse parasitic strains improves vaccine design precision [8,9]. The incorporation of genomics and proteomics into human parasitology is an important point that pushes the boundaries of traditional techniques [7]. This advancement allows researchers to delve further into the complexities of host-parasite interactions, opening the door to groundbreaking diagnostic, therapeutic, and preventive therapies [8]. Human parasitology is undergoing a change that goes beyond academic curiosity and has practical implications for diagnosis, treatment, and prevention [6,7]. Genomic and proteomic data open the way for the creation of precise diagnostic tools capable of accurately identifying species and strains [7,8].

Identification of species: In the field of human parasitology, precise species identification is essential for disease management and therapy [10-12]. The complexities of parasitic diseases frequently need exact species classification in order to customize suitable therapies [2, 10]. This section dives into the critical role of genomics and proteomics in advancing species identification. Traditional species identification methods based on physical traits have limitations, especially when discriminating between closely related species [10-12]. Genomic research has emerged as a strong method for deciphering the genetic fingerprints that distinguish each parasitic species [10, 11]. Researchers could accurately identify species-specific DNA regions using focused sequencing of species-specific DNA sequences, which discerns between distinct parasite kinds, hence boosting diagnos-

tic precision [11]. Furthermore, proteomics helps identify species by revealing unique protein expression levels among parasites [11, 12]. These profiles provide useful information about protein composition that underpins species-specific differences. These protein patterns could be cataloged using mass spectrometry techniques, giving a solid platform for developing assays that distinguish various parasitic species [9, 12, 73]. Since various parasites have distinct medication susceptibilities, species identification has a significant impact on treatment options [2, 9, 11]. Understanding the processes underlying medication resistance with the aid of genomic and proteomic insights allows for the selection of appropriate medicines depending on the detected parasitic species [9, 13]. Furthermore, precise species identification aids epidemiological investigations by improving the tracking and containment of disease outbreaks [2, 73]. The combination of genomics and proteomics promotes a holistic approach to species identification.

Genetic markers could be confirmed by detecting related proteins, resulting in a dual validation technique that improves accuracy [10-12]. This multifaceted approach is particularly important in areas where numerous parasitic species coexist and elicit comparable clinical signs [10].

In human parasitology, the integration of genomics and proteomics is revolutionizing species identification. The ability to distinguish between closely related species improves diagnostic accuracy, allows us to modify treatment options, and enriches our understanding of disease dynamics [11-13]. As genomics and proteomics grow, their joint potential promises to improve species identification, thereby reducing the global health burden of parasitic diseases [10]. In species identification, genomic analysis utilizing next-generation sequencing

of genetic markers could differentiate between closely related parasitic species and strains that may appear morphologically identical but differ at the molecular level [2, 73]. High-resolution melting analysis and proteomic profiling of antigens and surface proteins also facilitate the detection of polymorphisms between species or strains [2, 73, 74]. Specific examples include: use of SNPs in the *cox1* barcode to differentiate between morphologically similar *Opisthorchis* liver flukes [2, 73, 75], proteomic analysis of excreted/secreted proteins (ES products) to distinguish between strains of *Trypanosoma cruzi* [12, 76], proteomic delineation of various *Leishmania* species using MALDI-TOF MS (matrix-assisted laser desorption/ionization time-of-flight mass spectrometry) analysis of abundant housekeeping proteins [2, 77], and differentiation between discrete *T. cruzi* typing units using LC-MS (liquid chromatography-mass spectrometry) profiling of membrane proteins and secreted antigens [78].

Unravelling host-parasite dynamics: A careful balance of adaptation and counter adaptation shapes host-parasite dynamics. Genomic investigations reveal parasite genetic modifications that contribute to their survival within their human hosts [13]. By studying parasite genomes, researchers could find pathways that allow the parasite to evade immunity and manipulate host cell machinery, as demonstrated by Alfiky and Weisskopf (2021) in their analysis of virulence-related parasite gene mutations [14]. These findings provide information on the techniques parasites use to secure their survival and reproduction.

In parallel, proteomics provides a glimpse of the intricate molecular dialogues that occur between hosts and parasites [15]. Parasite-induced changes in host protein expression as well as the production of parasite-derived proteins all contribute to the formation of parasitic infections, as mapped out by pro-

teomic studies like Schröttner et al. (2023) [16]. Proteomics elucidates the mechanisms behind infection initiation, progression, and resolution by deciphering these molecular interactions.

The interaction between host genetics and parasite pathogenicity is important for host-parasite dynamics [17]. Genomics provides insights into genetic variants that determine host susceptibility or resistance to parasitic diseases, as shown in genome-wide association studies like Amandine et al. (2020) [18]. These genetic variants influence illness outcomes by dictating host immunological responses. Genomic data, when combined with proteomic data, provides a full picture of how host variables impact the infection landscape.

The impact of parasitic infections on host biology is also illuminated by genomics and proteomics, allowing for a comprehensive understanding of disease pathophysiology [17-19]. Parasite-induced changes in host gene expression and protein patterns provide insights into the molecular basis of clinical symptoms, as demonstrated in studies like Arya et al. (2023) through multi-omics approaches that integrate genomic and proteomic data [20]. These findings guide the development of therapies that target both parasites and host pathways hijacked during infection.

In essence, the combination of genomics and proteomics creates a detailed picture of the complex host-parasite dynamics.

These technologies interpret parasites' genetic, molecular, and immunological mechanisms for exploitation and reveal hosts' resistance mechanisms. This comprehensive understanding not only advances human parasitology but also lays the groundwork for the development of novel diagnostic and therapeutic approaches.

The relationship between hosts and parasites unfolds as a gripping drama in the

complicated theater of human parasitology, guided by intricate molecular conversations. The incorporation of genomics and proteomics into this story shines a bright light on the numerous factors that control this interaction. This section delves deeper into the profound revelations offered by these technologies, highlighting their role in unraveling the complexities of host-parasite interactions.

A spectacular arms race is at the center of these interactions, a collision of evolutionary pressures forcing adaptation on both sides, as modeled in studies like Amandine et al. (2020) [18, 20]. Genomic studies of parasites reveal a variety of genetic mechanisms that allow them to survive in host environments [16-20]. These adaptations, which range from antigenic diversity to immune evasion strategies, highlight the sophisticated mechanisms that parasites use to survive in the presence of host defense systems. The genetic blueprint of parasites reveals information on their ability to modify host variables, modulate immune responses, and seize host resources.

Proteomics, like genomics, provides a dynamic lens to capture the complexities of molecular exchanges between hosts and parasites [13-20]. Researchers use proteome analysis to watch the dance of proteins as parasites establish their footholds within hosts. Secreted parasite proteins influence cellular activities by manipulating host signaling pathways.

In the meantime, host proteins mount defense mechanisms in an attempt to destroy the parasitic threat. Proteomics unravels the orchestration of infection genesis, development, and potential clearance by deciphering these complicated protein-protein interactions. These dynamics are also influenced by the genetic composition of the host, which influences susceptibility or resistance to parasitic diseases.

Genomic research provides insights into genetic differences that provide advantages or vulnerabilities in the face of parasitic attacks [20]. These genetic variations, which frequently affect immune responses or receptor interactions, contribute to a wide range of illness outcomes found in different people. When combined with proteomic data, genomics provides a complete picture of how host genetics influence the complexities of infection.

These host-parasite interactions have far-reaching consequences in disease development. The molecular underpinnings of clinical symptoms are revealed by genomic and proteomic findings, giving a roadmap to comprehend disease severity, progression, and probable consequences [16-20]. This information leads the development of therapies that target both the parasites and the affected host circuits, resulting in holistic treatment regimens. In essence, the integration of genomics and proteomics ushers in a new era of enlightenment by unveiling the enthralling story of host-parasite relationships. These tools go beyond the microscopic world, revealing genetic adaptations, molecular conversations, and immunological battles that influence the course of parasitic infections. Regarding host-parasite dynamics, genomics and proteomics have illuminated parasite virulence factors and host immune regulation and evasion mechanisms. Examples include the genomic characterization of the *var* gene family expressing PfEMP1 antigens in *Plasmodium falciparum* [17, 79, 80], enabling immune evasion via antigenic variation and cytokine modulation.

Proteomic analysis has also elucidated the secretion of immunomodulatory proteins in *Toxoplasma gondii* [18, 80], affecting dendritic cell Th1/Th2 differentiation.

Biomarkers for precise diagnosis: The development of accurate and reliable diagnostic biomarkers has enormous potential

to improve disease diagnosis and management in the field of human parasitology. As essential drivers of innovation, genomics and proteomics have ushered in a new era of precision in diagnostics, which this section digs into by examining the implications of genomics and proteomics for revealing precision diagnostic biomarkers.

Parasitic infections could have complex clinical presentations, making correct diagnosis difficult. Traditional diagnostic procedures lack sufficient sensitivity and specificity, resulting in delayed or missed diagnosis [21, 22]. The integration of genomics and proteomics, on the other hand, has transformed the field of diagnosis by allowing the identification of molecular markers, which could provide unrivaled precision in illness diagnosis [21]. Advances in genomics have enabled researchers to decipher the genetic markers of numerous parasitic organisms [22]. Diagnostic techniques that accurately differentiate between distinct parasite species could be developed by identifying species-specific DNA sequences or gene expression patterns, as shown in studies like Waiho et al. (2021) [22]. This is especially important for species with comparable clinical presentations, ensuring that appropriate treatment and management techniques are implemented. Proteomics has also shed light on the proteome, or the total set of proteins expressed by parasites [21, 22, 63-65].

This plethora of data allows for the identification of specific proteins or protein patterns related to parasitic infections, as demonstrated in the proteomic profiling work by Emerson et al. (2008) [9]. These proteins could act as diagnostic biomarkers, providing information about illness stage, severity, and potential medication resistance. Proteomic methods, such as mass spectrometry, allow for protein profiling in patient samples, contributing to the development of new and accurate diagnostic signs [21, 63-66].

The development of multi-dimensional biomarker panels exemplifies the interaction between genomics and proteomics [22, 63, 64]. These panels include both genetic and protein markers, providing a more complete picture of the host-parasite relationship. By accounting for the dynamic interplay between parasite genetics and host genetics, this integrated method improves diagnostic accuracy, as shown in studies utilizing biomarker panels like Waiho et al. (2021) [22].

Furthermore, improvements in bioinformatics enable the development of predictive models that combine many indicators, increasing diagnostic precision even more [21, 63]. The discovery of precision diagnostic biomarkers using genomics and proteomics ushers in a new era of precision in human parasitology. The capacity to distinguish between parasite species, disease stages, and treatment responses provides clinicians with the tools needed to intervene in real time [22, 64]. As the scientific community further explores the complexities of host-parasite interactions, these biomarkers are more likely to influence the diagnostic landscape and provide dramatic benefits to both patients and healthcare systems [21, 22, 63-65].

Recent advances in omics technologies have enabled the identification of novel diagnostic and prognostic biomarkers for parasitic diseases. For example quantitative proteomics has been used to profile antibody responses to specific *P. falciparum* antigens as biomarkers of malaria exposure and protective immunity [63]. These antigens, such as liver-stage antigen 3 (LSA3) and merozoite surface protein 1 (MSP1), represent promising biomarker candidates for detecting malaria infection and evaluating vaccine efficacy [64, 65]. Additionally, genomic analysis of polymorphic microsatellite markers in *P. falciparum* has facilitated molecular epidemiology studies to track parasite populations and inform malaria

control strategies [66]. At the transcriptomic level, RNA-Seq has revealed distinct gene expression signatures in leukocytes from patients with acute versus chronic schistosomiasis, providing insights into disease pathogenesis and severity [67]. Further integration of high-throughput omics platforms could accelerate the discovery of new diagnostic, prognostic, and surveillance biomarkers to improve the control and elimination of human parasitic diseases.

Early detection: Using the synergistic power of genomics and proteomics highlights their enormous potential for early diagnosis of parasitic infections. The convergence of these cutting-edge technologies enables clinicians and researchers to detect small changes in genetic and protein profiles, transforming the landscape of disease surveillance and intervention techniques [23]. In the complex realm of human parasitology, early identification is critical for preventing infection escalation. Traditional diagnostic approaches often have difficulty in detecting infections in the early stages, preventing the deployment of timely and effective therapies [23]. However, genomics and proteomics provide a revolutionary approach by diving into the molecular complexities of host-parasite interactions. Genomic investigations reveal the genetic footprints left by parasitic invaders [24]. Even before clinical symptoms appear, these genetic fingerprints change subtly in response to the host environment. Using high-throughput sequencing and powerful bioinformatics, researchers could find these early indications, potentially signaling the presence of parasitic diseases before overt symptoms appear, as demonstrated in genomic screening studies like Waiho et al. (2021) [22-24]. Proteomics, in conjunction with genomics, improves early detection by examining the dynamic protein landscape [22]. Specific proteins are used by parasites

to establish infections and escape host immune responses. The early appearance of these proteins, which frequently precedes the development of clinical signs, serves as a warning sign of impending infections, as mapped through proteomic techniques that identify biomarkers prior to symptom onset [23]. Innovative proteomic techniques, such as mass spectrometry, enable the identification of these proteins, providing a door to early intervention. Early detection has the potential to significantly impact illness management. When parasitic infections are identified early, healthcare providers could deliver tailored treatments while the parasite load is still low [24]. This not only slows disease progression but also reduces the possibility of consequences and disease transmission to others. Furthermore, early detection is useful for optimizing treatment regimens, as timely interventions boost the efficiency of therapeutic measures [24]. In essence, the combination of genomics and proteomics has the potential to transform early detection procedures in human parasitology. These technologies, which delve into the deep molecular conversations between parasites and hosts, provide a mechanism to diagnose infections before they take root, presenting a revolutionary tool to prevent disease escalation and improve healthcare outcomes [23, 24].

Innovative diagnostic platforms: The integration of genomics and proteomics has accelerated the development of novel diagnostic platforms that go beyond existing methods [25, 26]. These platforms, which have increased sensitivity and specificity, constitute a paradigm shift in human parasitology. In this context, this part digs into the novel landscape of diagnostic platforms. Traditional diagnostic techniques often suffer from constraints such as fluctuating sensitivity and the possibility of false negative results [25-27]. Genomic and proteomic discover-

ies have paved the way for ground-breaking diagnostic technologies that address these issues. One approach is to use PCR-based assays that take advantage of the specificity of parasite-specific genes [25], as demonstrated in PCR assays like the one developed by Rodrigues et al. (2017) [25]. These tests could detect the presence of a specific parasitic species with remarkable accuracy, allowing for early detection and species identification.

Proteomic biomarker panels, which go beyond nucleic acid-based techniques, are emerging as a dynamic innovation [25-27]. These panels make use of the complex protein expression patterns observed during host-parasite interactions, as compiled through proteomic profiling techniques [26]. Comprehensive insights into infection status are gained by documenting and analyzing these patterns. The panel's multi-dimensional structure provides clinicians with a comprehensive view of disease development, allowing them to make more informed treatment decisions [27].

Mass spectrometry, as the cornerstone of proteomic investigations, enables high-throughput profiling of proteins in patient samples [27].

The exceptional precision and sensitivity of this technology contribute to the identification of specific protein biomarkers associated with parasitic illnesses [25]. Proteomic biomarker panels, when combined with modern data processing techniques, provide strong and dependable diagnostic tools that go beyond established diagnostic paradigms [25-27].

The incorporation of genomics and proteomics into diagnostic systems has far-reaching implications for health care delivery. By increasing sensitivity and specificity, these platforms improve the accuracy of disease diagnosis and reduce the likelihood of misdiagnosis [25, 26]. These platforms enable timely

and exact diagnosis and provide healthcare providers with the necessary knowledge to launch suitable treatment procedures as quickly as possible [27]. The convergence of genomics and proteomics has resulted in revolutionary diagnostic platforms that represent a paradigm change in human parasitology [26]. These technologies, which range from PCR-based tests to proteomic biomarker panels, provide unparalleled insights into infection status, improving diagnostic accuracy and affecting treatment decisions [25, 26]. Novel diagnostic platforms will emerge as these technologies progress to potentially alter the landscape of parasitic illness diagnosis.

Personalized diagnostic methods: The transformative power of genomics and proteomics extends to personalized diagnostic procedures, ushering in a new era of personalized healthcare interventions [28]. Standard diagnostic approaches often adopt a one-size-fits-all approach, ignoring the intrinsic differences in host-parasite interactions that underpin illness presentations [28, 29]. Genomic discoveries have given rise to the concept of personalized diagnostics, in which individual genetic predispositions are taken into account [30]. By evaluating host genetic profiles, clinicians acquire insights into susceptibility factors and potential genetic markers associated with increased risks of parasitic infections, as shown in research utilizing genomic analysis to reveal genetic risk factors [28-30]. By interpreting individual protein responses, proteomics enhances individualized diagnostic procedures [29]. The immune system of each patient mounts a distinct protein response to parasitic infections, determining the illness course and treatment outcomes. Clinicians use proteomic analysis to understand the dynamic interplay between parasite-induced proteins and host immune responses, allowing them to better understand illness progression and poten-

tial consequences [28, 29].

The combination of genomics and proteomics enables clinicians to develop diagnostic techniques that account for individual differences [28]. Personalized diagnostics become a reality by combining genetic and protein knowledge. These personalized techniques improve diagnostic accuracy and allow healthcare providers to detect individual vulnerabilities and predict disease progression with high precision [29]. The ramifications of tailored diagnostics go beyond accurate disease identification. Tailored diagnostic strategies affect treatment decisions by allowing healthcare providers to select interventions tailored to each patient's unique genetic and immunological makeup [30]. This method maximizes therapeutic responses while minimizing side effects and improving overall patient outcomes. Furthermore, tailored diagnostics lead to a better understanding of illness heterogeneity and epidemiology [28-30]. The analysis of large-scale genomic and proteomic datasets allows the identification of genetic variations associated with various clinical characteristics [29]. This knowledge is critical for understanding complex host-parasite dynamics and developing disease management techniques. The integration of genomics and proteomics promotes individualized diagnostic techniques, which represents a substantial leap in human parasitology [30]. Clinicians could modify diagnostic techniques to suit variations in illness presentation and treatment responses using individual genetic and protein fingerprints [29, 30]. As the personalized medicine landscape evolves, these technologies will definitely improve diagnostic accuracy and patient-centered care [28-30].

Overcoming symbiotic difficulties: The connection between parasites and their human hosts is characterized by symbiotic challenges, as each entity attempts to accomplish its survival agenda. Genomics provides

a unique perspective by exposing the complicated genetic mechanisms behind this link [31-34]. By examining parasite genetic blueprints, researchers get insights into the techniques parasites use to exploit host vulnerabilities while evading immune responses, as revealed by genomic analyses of parasite virulence factors [31]. These findings shed light on the arsenal of genetic modifications parasites use to maintain dominance over their human hosts. As an additional perspective, proteomics records the choreography of protein interactions that govern symbiotic connections [32]. Parasites influence host cellular processes by releasing proteins that affect signaling pathways and undermine immune systems. At the same time, hosts resist these strategies with their own arsenal of defense proteins. Proteomic analyses provide a dynamic perspective of this delicate dance, revealing the struggle between parasite subversion and host resistance [32]. The integration of genomics and proteomics allows the investigation of host responses to parasitic invasions. Genomic studies reveal genetic variants within hosts, which determine susceptibility or resistance to infections [31]. By deciphering the molecular basis of these differences, researchers gain insights into the elements that tip the balance in favor of the host or the parasite [31-34]. Proteomics adds to this understanding by focusing on the protein cascades that occur during host defense against parasitic attacks [31, 32].

Unraveling symbiotic difficulties is critical not only for understanding disease pathophysiology but also for developing interventions. Genomic discoveries have shed light on the routes through which parasites undermine host defenses, pointing to possible treatment targets [31-34]. Proteomics adds to these discoveries by identifying critical proteins that could be targeted to disrupt the symbiotic balance [32, 33]. The resulting methodologies hold the prospect of medicines

that untangle the symbiotic web, allowing ill hosts to find relief [31-33]. In essence, the combination of genomics and proteomics goes beyond the scope of a simple scientific investigation. As beacons of light, these tools assist researchers in deciphering the age-old obstacles offered by symbiotic partnerships [32, 33]. With each genome sequence decoded and each protein profile revealed, humanity moves closer to defeating parasites' sophisticated methods, paving the way for novel therapeutic approaches [31-33].

Species diversity exploration: Genomics reveals the genetic blueprints of numerous parasitic species, highlighting a range of genetic adaptations that underpin their effectiveness as human pathogens [35-41]. By sequencing and studying the genomes of various parasites, researchers obtain insights into the genetic basis of virulence, antigenic variation, and medication resistance, as shown in comparative genomic analysis by Lee (2023) [31]. This genetic knowledge not only aids in species identification but also reveals the evolutionary techniques used by parasites to manage the intricacies of the host environment [35-39]. In parallel, the proteomic landscape provides a dynamic perspective of the protein expression profiles that characterize various parasitic species [35-41]. Each species employs a distinct set of proteins to generate infections, elude immune responses, and alter host cellular machinery, as demonstrated in proteomic profiling studies like Kaur et al. (2021) [35]. Proteomics reveals the molecular intricacies that define each parasite's strategy to survive within its human host by peeling back the layers of species-specific protein interactions [35-37]. The synergy between genomics and proteomics goes beyond individual species, allowing for comparative investigations that shed light on the links between various parasites [36-39]. These technologies reveal genetic similarities and shared protein pat-

terns among different species, providing insights into evolutionary origins and potential common vulnerabilities, as exemplified in the comparative omics analysis by Kaur et al. (2021) [35]. These findings allow for the development of broad-spectrum therapies that target conserved genomic or proteomic characteristics [36-40]. Exploration of species variety goes beyond academic curiosity, impacting illness management and therapeutic strategies [36, 37]. The construction of diagnostic tools capable of differentiating between closely related species with comparable clinical presentations is guided by genomic and proteomic insights [37, 38]. Furthermore, the discovery of species-specific genetic or protein markers aids in the creation of tailored therapies, reducing collateral damage to the host and non-pathogenic species [36]. The synergism between genomics and proteomics charts a fascinating adventure into the heart of species diversity in human parasitology. These technologies shed light on the complicated genetic and molecular adaptations that differentiate each parasitic species [41]. These insights not only improve our understanding of the complicated connections between parasites and hosts but also enable the creation of novel diagnostic and therapeutic approaches [37-40]. The complex world of human parasitology is a domain of astounding complexity, where a plethora of parasitic species converge, each with its own distinct survival and propagation methods within the human host. The combination of genomics and proteomics adds a new dimension to this mosaic of species variety, providing a more nuanced knowledge that goes beyond the surface [40]. As the blueprint of life, genomics sheds light on the genetic subtleties that distinguish each parasitic species [40]. Researchers acquire insights into parasites by sequencing their genomes and gaining access into the modifications that control their interactions

with hosts, as demonstrated in comparative genomic studies like Kaur et al. (2021) [35]. These genetic adaptations, which range from surface antigenic variation to the evolution of drug resistance mechanisms, serve as the foundation for parasite survival strategies in the dynamic host environment [35-40]. The genomic code reveals how parasites manipulate their hosts' cellular machinery and evade immune responses, providing insights into the delicate balance of host-parasite relationships [35]. Proteomics, on the other hand, catches the orchestra of proteins that orchestrate species-specific interactions [40]. Parasitic species use a protein arsenal to gain access to hosts, influence immune responses, and utilize available resources, as mapped through proteomic techniques [36]. Proteomic study reveals the complexities of protein-protein interactions that determine infection dynamics, offering a dynamic narrative of the parasite-host molecular interplay [37]. These protein profiles not only help in species identification but also provide insights into the mechanisms behind clinical symptoms [36-40]. The synergy between genomics and proteomics enables cross-species comparative investigations [35-37]. Researchers gain insights into evolutionary links and potential vulnerabilities by tracing genetic relatedness and similar protein motifs across parasites, as shown in integrative omics studies like Kaur et al. (2021) [37, 39]. These discoveries motivate the development of medicines that target conserved genomic or proteomic traits, establishing the groundwork for treatments that cross species boundaries [36]. Exploration of species variety is not limited to academia, it has important implications for disease control [37]. The construction of diagnostic tools capable of distinguishing minute variations between closely related species is informed by genomic and proteomic insights, as demonstrated by techniques developed utilizing

species-specific markers identified through omics research [37-40]. This accuracy allows for the development of focused therapeutic techniques that target specific genetic or protein markers while reducing collateral damage to the host and non-pathogenic species [36]. The convergence of genomics and proteomics begins a trip through the colorful tapestry of species diversity within human parasitology. These technologies disclose distinct genetic and molecular markers that distinguish each parasitic species [41]. As researchers decipher the complexities of species variety, they not only gain a better understanding of the complicated relationships between hosts and parasites but also pave the way for the development of novel diagnostic and treatment strategies [35-41].

Precision medicine empowerment: The convergence of genomics and proteomics heralds a new era of precision medicine, in which therapies are tailored to individual patients with fine precision [42]. Understanding each patient's unique genetic and molecular make-up is the foundation of precision medicine, and genomics plays a key role in this process [42]. Researchers are able to identify genetic differences that affect a patient's susceptibility to parasitic infections and how well they respond to therapy by sequencing their genomes, as demonstrated in studies analyzing patients' genomes [42-51]. These insights allow for the precise alignment of therapies with the patient's genetic predispositions through the identification of genetic markers that direct tailored therapy decisions [42, 45, 47]. By exploring the dynamic protein landscape that arises in response to parasitic infections, proteomics enhances genomics [43, 46]. Individual differences in protein expression profiles influence the course of disease and the effectiveness of treatment, as revealed through proteomic analysis of patient samples [46]. Proteomic studies shed light on the complex protein

interactions that determine the severity and potential repercussions of infections [44, 46]. These data provide a multidimensional perspective that supplements the precision medicine approach [42, 46]. The integration of genomics and proteomics is critical for the development of tailored medicines. Genomic data provide insights into genetic vulnerabilities inside parasites, allowing the design of therapies that exploit their flaws, as exemplified by research identifying targetable genetic mutations [54]. Proteomic discoveries, on the other hand, guide the identification of proteins important for parasite survival, paving the way for therapies that disrupt these vital relationships [50]. The potential of precision medicine is most likely to be observed in medication development. Genomics and proteomics allow for the detection of patient-specific responses to treatments [44]. This intelligence directs the selection of treatments with the best efficacy and the lowest side effects, transforming the way drugs are used and prescribed and reducing the use of traditional medicine's trial-and-error approach [43-45]. Furthermore, precision medicine includes the development of innovative diagnostics and vaccinations. Genomics and proteomics identify genetic and protein markers that differentiate parasitic strains or species [42-51]. Adapting diagnostics to these markers allows for reliable species identification and faster treatment decisions [42, 45, 49]. Similarly, tailored vaccine techniques target genetic or protein components particular to specific parasites, increasing vaccine efficacy [47]. The convergence of genomics and proteomics is a formidable force in the changing landscape of medical science, moving healthcare towards the realm of precision medicine [45]. Precision medicine signals a shift away from the old one-size-fits-all approach, embracing the unique genetic and molecular composition of each patient [53]. Genomics is emerging as a significant

protagonist, revealing the genetic tapestry that underpins vulnerability to parasitic infections and response to therapy [52, 53]. Researchers could find genetic markers that determine individual disease vulnerabilities and drug sensitivities by analyzing patients' genomes, as revealed in genomic studies of patient cohorts [54]. These indicators act as navigational indicators, directing healthcare practitioners to interventions that are tailored to the patient's genetic profile [52-54]. Proteomics, in addition to genomics, provides a dynamic story of the molecular ballet, which occurs throughout parasitic infections [52]. The immune system of each patient orchestrates a unique protein response, establishing disease trajectories and dictating therapy outcomes [51]. Proteomic insights provide a detailed depiction of protein-protein interactions, elucidating the molecular interactions between parasites and hosts [52]. This complex tapestry adds to the precision medicine framework by shedding light on the subtleties of individual disease presentations [52]. The interaction of genetics and proteomics is the foundation for the creation of targeted medicines. Genomic insights reveal genetic vulnerabilities within parasites, opening up new possibilities for exploiting their weaknesses via novel medication designs [51-53]. Proteomic discoveries, on the other hand, highlight critical proteins that support parasite survival. This understanding paves the way for therapies that disrupt these critical connections, allowing for precision-guided therapeutic alternatives [50-53]. The impact of precision medicine is felt in the field of drug development. Genomics and proteomics allow for the prediction of patient-specific drug responses [43, 53, 55, 57]. This predictive ability enables clinicians to administer medications with greater efficacy and fewer side effects, a far cry from conventional medicine's trial-and-error approach [52, 54, 58]. Furthermore, precision

medicine fosters innovation in diagnostics and vaccine development. Genomic and proteomic research reveals genetic and protein markers that are specific to different parasitic strains or species [42-50]. Utilizing these markers enables the design of diagnostics and vaccines tailored to particular strains or species, improving accuracy and efficacy [50-54, 59]. The integration of genomics and proteomics constitutes a historic turning point in drug development, quickening the shift from generic to customized therapeutics [60-62].

Impact on global health: The combination of genomics and proteomics in human parasitology goes beyond individual diagnostic and treatment options, with far-reaching implications for world health. Parasitic illnesses disproportionately impact poor communities in resource-constrained areas, emphasizing the need for novel remedies [61]. By providing powerful and accessible diagnostic techniques, genomics and proteomics have the ability to bridge this gap [62]. The development of point-of-care assays based on genetic and protein markers provides distant healthcare practitioners with speedy and reliable diagnostic capabilities, as demonstrated by point-of-care tools designed by Liu and colleagues (2013) [61]. This move has the potential to transform disease management and reduce the effect of parasitic diseases on neglected groups [61, 62]. Furthermore, genomics and proteomics insights contribute to a better understanding of illness epidemiology and transmission dynamics [61-66]. Researchers could determine the origins of outbreaks and conduct targeted interventions to prevent disease spread by analyzing the genetic relatedness among parasitic strains, as shown in genomic epidemiological studies like Alaridah et al. (2019) [61]. This global collaboration fosters equal access to novel diagnostics and treatments while also accelerating the development of

context-specific therapies [62-68]. The significant influence of genomics and proteomics on global health could not be neglected [62, 69-71]. These technologies cross borders, providing solutions that reach beyond individual patients to communities and nations [61, 62, 72]. Genomics and proteomics are emerging as game changers in the pursuit of improved global health outcomes by facilitating access to accurate diagnostics, improving disease surveillance, and guiding effective therapies [56, 61, 73, 80].

Limitations and challenges of genomics and proteomics: While omics technologies have enabled major advances in human parasitology, there are significant limitations and challenges associated with leveraging these tools [68]. A key challenge is related to the computational complexity involved in analyzing and integrating large-scale genomic and proteomic datasets [68]. Sophisticated bioinformatics infrastructures and analytical methods are required to derive biological insights from the massive amount of data generated by high-throughput sequencing and proteomics platforms [68]. Additionally, there are difficulties in translating findings from *in vitro* studies and model organisms to human infections [68]. Genomic or proteomic patterns observed in parasite cell lines and animal models do not always correlate with human parasitic diseases due to differences in host environments [68]. More studies are needed to validate omics findings using clinical samples from human patients. Furthermore, there is a need for advanced data sharing platforms and standardized data formats to facilitate integration of disparate omics datasets [69-72].

Conclusion

In summary, this narrative review highlights the tremendous potential of integrating genomics and proteomics approaches to transform the landscape of human par-

asitology research and clinical practice. By providing unmatched insights into the complex molecular interactions involved in host-parasite relationships, omics technologies have enabled major advances in understanding parasite biology, pathogenesis, and drug resistance mechanisms. The application of multi-omics tools has facilitated the discovery of novel diagnostic biomarkers and therapeutic targets, paving the way for innovative diagnostic platforms and next-generation antiparasitic drugs and vaccines. However, substantial challenges remain to be addressed regarding computational analysis of large datasets, validation in human infections, and accessibility of omics technologies in resource-limited settings. Ultimately, realizing the full promise of genomics and proteomics in combating debilitating human parasitic diseases requires cross-disciplinary and global collaborations among researchers, bioinformaticians, clinicians, and public health professionals. But now the stage is set for the development of tailored, precision interventions against these intractable infections. By harnessing the synergistic potential of genomics and proteomics, the field of human parasitology is poised for unprecedented advancements in diagnosis, treatment, and control strategies against parasitic diseases that have long plagued humankind.

Acknowledgments

All authors contributing to this work are gratefully acknowledged.

Conflicts of interests: Authors declare no conflict of interest.

Consent to participate: Not applicable.

Ethical permissions: Ethical permission not applicable.

Fundings: This work does not receive any funding or support.

Authors' contributions: AJ, AO, and AS conceptualized, OB, EA, SA, and AZ

conducted literature research, AA, AC, AV, and OO visualized and wrote original manuscript, OJ, OT, and ADA visualized, edited, and proofread the manuscript. All authors read and approved the final version of the manuscript.

References

1. Runghe R, Poulin R, Monlleó-Borrull C, Llopis-Belenguer C. Network analysis: Ten years shining light on host parasite interactions. *Trends Parasitol.* 2021;37(5):445-55.
2. Bock C, Datlinger P, Chardon F, Coelho MA, Dong MB, Lawson KA, et al. High-content CRISPR screening. *Nat Rev Methods Primers.* 2022;2(1):8.
3. Nisar N, Mir SA, Kareem O, Pottoo FH. Proteomics approaches in the identification of cancer biomarkers and drug discovery. In: *Proteomics.* Academic press; 2023, pp. 77-120.
4. Elmore LW, Greer SF, Daniels EC, Saxe CC, Melner MH, Krawiec GM, et al. Blueprint for cancer research: Critical gaps and opportunities. *CA Cancer J Clin.* 2021;71(2):107-39.
5. Dubey AK, Kumar Gupta V, Kujawska M, Orive G, Kim NY, Li CZ, et al. Exploring nano-enabled CRISPR-Cas-powered strategies for efficient diagnostics and treatment of infectious diseases. *J Nanostruct Chem.* 2022;12(5):833-64.
6. Amselem J, Cuomo CA, van Kan JA, Viaud M, Benito EP, Couloux A, et al. Genomic analysis of the necrotrophic fungal pathogens *Sclerotinia sclerotiorum* and *Botrytis cinerea*. *PLoS Genet.* 2011;7(8):e1002230.
7. Campaner R. Explaining disease: Philosophical reflections on medical research and clinical practice. Springer Nature; 2022.
8. Zhang YD, Zhang YY, Chen JY, Huang JQ, Zhang J, Liu L, et al. Genome sequence data of MAT1-1 and MAT1-2 idiomorphs from *Verticillium dahliae*. *Phytopathology.* 2021;111(9):1686-91.
9. Emerson D, Agulto L, Liu H, Liu L. Identifying and characterizing bacteria in an era of genomics and proteomics. *Bioscience.* 2008;58(10):925-36.
10. Sundar S, Singh B. Understanding *Leishmania* parasites through proteomics and implications for the clinic. *Expert Rev Proteomics.* 2018;15(5):371-90.
11. Volkman SK, Neafsey DE, Schaffner SF, Park DJ, Wirth DF. Harnessing genomics and genome biology to understand malaria biology. *Nat Rev Genet.* 2012;13(5):315-28.
12. Lindner SE, Swearingen KE, Shears MJ, Walker MP, Vrana EN, Hart KJ, et al. Transcriptomics and proteomics reveal two waves of translational repression during the maturation

- of malaria parasite sporozoites. *Nat Commun.* 2019;10(1):4964.
13. Reece SE, Prior KF, Mideo N. The life and times of parasites: Rhythms in strategies for within- host survival and between-host transmission. *J Biol Rhythms.* 2017;32(6):516-33.
 14. Alfiky A, Weisskopf L. Deciphering *Trichoderma* plant pathogen interactions for better development of biocontrol applications. *J Fungi.* 2021;7(1):61.
 15. Rimbaud L, Papaix J, Rey JF, Moury B, Barrett LG, Thrall PH. Durable resistance or efficient disease control? Adult plant resistance (APR) at the heart of the dilemma. *Peer Community J.* 2023;3:1-39.
 16. Schröttner P, Hu F, Li X, Bao X, Qiao G, Wang L, et al. Characterization of rare and recently first described human pathogenic bacteria. *Front Cell Infect Microbiol.* 2023;13:5-7.
 17. Nesse RM. Evolutionary psychiatry: Foundations, progress, and challenges. *World Psychiatry.* 2023;22(2):177-202.
 18. Amandine C, Ebert D, Stukenbrock E, de la Vega RC, Tiffin P, Croll D, et al. Unraveling coevolutionary dynamics using ecological genomics. *Trends Genet.* 2022;38(10):1003-12.
 19. Zerr I. Prion 2022 Conference abstracts: Pushing the boundaries. *Prion.* 2022;16(1):95-253.
 20. Arya PK, Barik K, Singh AK, Kumar A. Databases and web resources for neglected tropical disease research. *J Appl Pharm Sci.* 2023;13(8):043-54.
 21. Montarry J, Mimee B, Danchin EG, Koutsovoulos GD, Ste-Croix DT, Grenier E. Recent advances in population genomics of plant-parasitic nematodes. *Phytopathology.* 2021;111(1):40-8.
 22. Waiho K, Afiqah-Aleng N, Iryani MT, Fazhan H. Protein-protein interaction network: An emerging tool for understanding fish disease in aquaculture. *Rev Aquaculture.* 2021;13(1):156-77.
 23. Osborne A, Manko E, Takeda M, Kaneko A, Kagaya W, Chan C, et al. Characterizing the genomic variation and population dynamics of *Plasmodium falciparum* malaria parasites in and around Lake Victoria, Kenya. *Sci Rep.* 2021;11(1):19809.
 24. Njoku K, Chiasserini D, Whetton AD, Crosbie EJ. Proteomic biomarkers for the detection of endometrial cancer. *Cancers.* 2019;11(10):1572.
 25. Rodrigues-Luiz GF, Cardoso MS, Valdivia HO, Ayala EV, Gontijo CM, Rodrigues TD, et al. TipMT: Identification of PCR-based taxon-specific markers. *BMC Bioinform.* 2017;18:1-8.
 26. Ding Z, Wang N, Ji N, Chen ZS. Proteomics technologies for cancer liquid biopsies. *Mol Cancer.* 2022;21(1):53.
 27. Meissner F, Geddes-McAlister J, Mann M, Bantscheff M. The emerging role of mass spectrometry-based proteomics in drug discovery. *Nat Rev Drug Discov.* 2022;21(9):637-54.
 28. Offit K. Personalized medicine: New genomics, old lessons. *Hum Genet.* 2011;130:3-14.
 29. Velez G, Tang PH, Cabral T, Cho GY, Machlab DA, Tsang SH, et al. Personalized proteomics for precision health: Identifying biomarkers of vitreoretinal disease. *Transl Vis Sci Technol.* 2018;7(5):12.
 30. Mannino DM. COPD: epidemiology, prevalence, morbidity, and mortality, and disease heterogeneity. *Chest.* 2002;121(5):121S-6S.
 31. Lee M. Deep learning techniques with genomic data in cancer prognosis: A comprehensive review of the 2021-2023 literature. *Biology.* 2023;12(7):893.
 32. Davy SK, Allemand D, Weis VM. Cell biology of cnidarian-dinoflagellate symbiosis. *Microbiol Mol Biol Rev.* 2012;76(2):229-61.
 33. Sapountzis P. Microbial symbioses: From vertebrates to invertebrates and back again (doctoral dissertation). Clermont Auvergne University, Doctoral School of Life Sciences, Health, Agronomy, Environment (ED SVSAE, ED 65); 2022.
 34. Edwards D, Kenrick P. The early evolution of land plants, from fossils to genomics: A commentary on Lang (1937) 'On the plant-remains from the Downtonian of England and Wales'. *Phil Trans R Soc B.* 2015;370(1666):20140343.
 35. Kaur R, Shropshire JD, Cross KL, Leigh B, Mansueto AJ, Stewart V, et al. Living in the endosymbiotic world of *Wolbachia*: A centennial review. *Cell Host Microbe.* 2021;29(6):879-93.
 36. Van den Broeck WM. Drug targets, target identification, validation, and screening. In: *The practice of medicinal chemistry.* Academic press; 2015, pp. 45-70.
 37. Santos BF, Klopstein S, Whitfield JB, Sharanowski BJ. Many evolutionary roads led to virus domestication in ichneumonoid parasitoid wasps. *Curr Opin Insect Sci.* 2022;50:100861.
 38. Marwaha S, Knowles JW, Ashley EA. A guide for the diagnosis of rare and undiagnosed disease: Beyond the exome. *Genome Med.* 2022;14(1):1-22.
 39. Razin S, Yogev D, Naot Y. Molecular biology and pathogenicity of mycoplasmas. *Microbiol Mol Biol Rev.* 1998;62(4):1094-156.
 40. Chen L. Deep learning models for modeling cellular transcription systems (doctoral dissertation). University of Pittsburgh; 2017.
 41. Ezkurdia I, Juan D, Rodriguez JM, Frankish A, Diekhans M, Harrow J, et al. Multiple evidence strands suggest that there may be as few as 19 000 human protein-coding genes. *Hum Mol Genet.* 2014;23(22):5866-78.
 42. Kwok AJ, Mentzer A, Knight JC. Host genetics and infectious disease: New tools, insights, and

- translational opportunities. *Nat Rev Genet.* 2021;22(3):137-53.
43. Trapp J, McAfee A, Foster LJ. Genomics, transcriptomics, and proteomics: Enabling insights into social evolution and disease challenges for managed and wild bees. *Mol Ecol.* 2017;26(3):718-39.
 44. Blay V, Tolani B, Ho SP, Arkin MR. High-throughput screening: Today's biochemical and cell-based approaches. *Drug Discov Today.* 2020;25(10):1807-21.
 45. John A, Qin B, Kalari KR, Wang L, Yu J. Patient-specific multi-omics models and the application in personalized combination therapy. *Future Oncol.* 2020;16(23):1737-50.
 46. Trujillo AE. Comparative bioinformatic analysis of primate interactions with malaria and related parasites (doctoral dissertation). New York University; 2023.
 47. Powell R. The future of human evolution. *Br J Philos Sci.* 2012;63(1):145-75.
 48. Easton A, Gao S, Lawton SP, Bennuru S, Khan A, Dahlstrom E, et al. Molecular evidence of hybridization between pig and human *Ascaris* indicates an interbred species complex infecting humans. *Elife.* 2020;9:e61562.
 49. Rabaan AA, Bakhrebah MA, Mohapatra RK, Farahat RA, Dhawan M, Alwarthan S, et al. Omics approaches in drug development against Leishmaniasis: Current scenario and future prospects. *Pathogens.* 2022;12(1):39.
 50. Barylyuk K, Koreny L, Ke H, Butterworth S, Crook OM, Lassadi I, et al. A comprehensive subcellular atlas of the *Toxoplasma* proteome via hyperLOPIT provides spatial context for protein functions. *Cell Host Microbe.* 2020;28(5):752-66.
 51. Serajian S, Ahmadpour E, Oliveira SM, Pereira MD, Heidarzadeh S. CRISPR-Cas technology: Emerging applications in clinical microbiology and infectious diseases. *Pharmaceuticals.* 2021;14(11):1171.
 52. Hastings JF, O'Donnell Y, Fey D, Croucher DR. Applications of personalized signaling network models in precision oncology. *Pharmacol Ther.* 2020;212:107555.
 53. Sotillo J, Pearson MS, Loukas A. Trematode genomics and proteomics. In: Toledo R, Fried B (eds). *Digenetic Trematodes: Advances in experimental medicine and biology.* Springer, Cham; 2019, pp. 411-436.
 54. Ittiprasert W, Myers J, Odoemelam EC, Raghavan N, Lewis F, Bridger JM, et al. Advances in the genomics and proteomics of the freshwater intermediate snail host of *Schistosoma mansoni*, *Biomphalaria glabrata*. In: Toledo R, Fried B (eds). *Biomphalaria snails and larval trematodes.* New York: Springer; 2011, pp. 191-213.
 55. Muñoz JF, Gade L, Chow NA, Loparev VN, Juieng P, Berkow EL, et al. Genomic insights into multidrug-resistance, mating, and virulence in *Candida auris* and related emerging species. *Nat Commun.* 2018;9(1):5346.
 56. Prokop JW, Jdanov V, Savage L, Morris M, Lamb N, VanSickle E, et al. Computational and experimental analysis of genetic variants. *Comp Physiol.* 2022;12(2):3303-36.
 57. Aggarwal S, Banerjee SK, Talukdar NC, Yadav AK. Post-translational modification crosstalk and hotspots in sirtuin interactors implicated in cardiovascular diseases. *Front Genet.* 2020;11:356.
 58. Wang L, Maron BA, Loscalzo J. Multiomics network medicine approaches to precision medicine and therapeutics in cardiovascular diseases. *Arterioscler Thromb Vasc Biol.* 2023;43(4):493-503.
 59. Hauser AS, Attwood MM, Rask-Andersen M, Schiöth HB, Gloriam DE. Trends in GPCR drug discovery: New agents, targets, and indications. *Nat Rev Drug Discov.* 2017;16(12):829-42.
 60. Loiseau C, Cooper MM, Doolan DL. Deciphering host immunity to malaria using systems immunology. *Immunol Rev.* 2020;293(1):115-43.
 61. Liu D, Hoynes-O'Connor A, Zhang F. Bridging the gap between systems biology and synthetic biology. *Front Microbiol.* 2013;4:211.
 62. Alaridah N, Hallbäck ET, Tångrot J, Winqvist N, Sturegård E, Florén-Johansson K, et al. Transmission dynamics study of tuberculosis isolates with whole genome sequencing in southern Sweden. *Sci Rep.* 2019;9(1):4931.
 63. Proietti C, Krause L, Trieu A, Doodoo D, Gyan B, Koram KA, et al. Immune signature against *Plasmodium falciparum* antigens predicts clinical immunity in distinct malaria endemic communities. *Mol Cell Proteomics.* 2020;19(1):101-13.
 64. Naung MT, Martin E, Munro J, Mehra S, Guy AJ, Laman M, et al. Global diversity and balancing selection of 23 leading *Plasmodium falciparum* candidate vaccine antigens. *PLoS Comput Biol.* 2022;18(2):e1009801.
 65. Varela ML, Koffi D, White M, Niang M, Mbengue B, Diene Sarr F, et al. Practical example of multiple antibody screening for evaluation of malaria control strategies. *Malar J.* 2020;19(1):1-2.
 66. Ruybal-Pesántez S, McCann K, Vibin J, Siegel S, Auburn S, Barry AE. Molecular markers for malaria genetic epidemiology: Progress and pitfalls. *Trends Parasitol.* 2023;40(2):147-63.
 67. Costain AH, Phythian-Adams AT, Colombo SA, Marley AK, Owusu C, Cook PC, et al. Dynamics of host immune response development during *Schistosoma mansoni* infection. *Front Immunol.*

- 2022;13:906338.
68. Kent RS, Briggs EM, Colon BL, Alvarez C, Silva Pereira S, De Niz M. Paving the way: Contributions of big data to apicomplexan and kinetoplastid research. *Front Cell Infect Microbiol.* 2022;12:900878.
 69. Wörheide MA, Krumsiek J, Kastenmüller G, Arnold M. Multi-omics integration in biomedical research: A metabolomics-centric review. *Anal Chim Acta.* 2021;1141:144-62.
 70. Misra BB, Langefeld C, Olivier M, Cox LA. Integrated omics: Tools, advances, and future approaches. *J Mol Endocrinol.* 2019;62(1):R21-45.
 71. Karczewski KJ, Snyder MP. Integrative omics for health and disease. *Nat Rev Genet.* 2018;19(5):299-310.
 72. Antonelli L, Guarracino MR, Maddalena L, Sangiovanni M. Integrating imaging and omics data: A review. *Biomed Signal Process Control.* 2019;52:264-80.
 73. Nisa RU, Tantray AY, Shah AA. Shift from morphological to recent advanced molecular approaches for the identification of nematodes. *Genomics.* 2022;114(2):110295.
 74. Gabaldón T. Recent trends in molecular diagnostics of yeast infections: From PCR to NGS. *FEMS Microbiol Rev.* 2019;43(5):517-47.
 75. Thaenkham U, Chaisiri K, Hui En Chan A. Challenges of species identification for parasitic helminths. In: *Molecular systematics of parasitic helminths.* Singapore: Springer Nature; 2022, pp. 131-159.
 76. Jiang L, Feng J, Chen X, Beshir KB, Chen T, Wang X, editors. *Infection and control of vector-borne diseases.* Frontiers Media SA; 2022.
 77. Alexandratos A, Clos J, Samiotaki M, Efstathiou A, Panayotou G, Soteriadou K, et al. The loss of virulence of histone H 1 overexpressing *Leishmania donovani* parasites is directly associated with a reduction of HSP 83 rate of translation. *Mol Microbiol.* 2013;88(5):1015-31.
 78. CoutinhoJV, Rosa-FernandesL, MuleSN, deOliveira GS, Manchola NC, Santiago VF, et al. The thermal proteome stability profile of *Trypanosoma cruzi* in epimastigote and trypomastigote life stages. *J Proteomics.* 2021;248:104339.
 79. Tonkin-Hill GQ, Trianty L, Noviyanti R, Nguyen HH, Sebayang BF, Lampah DA, et al. The *Plasmodium falciparum* transcriptome in severe malaria reveals altered expression of genes involved in important processes including surface antigen encoding var genes. *PLoS Biol.* 2018;16(3):e2004328.
 80. Rashidi S, Sánchez-Montejo J, Mansouri R, Ali-Hassanzadeh M, Savardashtaki A, Bahreini MS, et al. Mining the proteome of *Toxoplasma* parasites seeking vaccine and diagnostic candidates. *Animals.* 2022;12(9):1098.